Inozyme Pharma Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Inozyme Pharma Inc Unternehmen

Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The Company is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The Company also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).

Unternehmensinformationen

Unternehmens-codeINZY

Name des UnternehmensInozyme Pharma Inc

IPO-datumJul 24, 2020

Gegründet am2015

CEODr. Douglas A. (Doug) Treco, Ph.D.

Anzahl der mitarbeiter67

WertpapierartOrdinary Share

GeschäftsjahresendeJul 24

Addresse321 Summer Street

StadtBOSTON

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl02210

Telefon18573304340

Websitehttps://www.inozyme.com/

Unternehmens-codeINZY

IPO-datumJul 24, 2020

Gegründet am2015

Führungskräfte

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Axel Bolte

Director

266.70K

--

Dr. Matthew Winton, Ph.D.

Chief Operations Officer

7.39K

--

Dr. Robert (Rob) Hopfner, Ph.D.

Independent Director

--

Dr. Martin William Edwards, M.D.

Independent Director

--

Mr. Edward T. Mathers

Independent Director

--

Dr. Sarah M. Bhagat, Ph.D.

Independent Director

--

Mr. Reinaldo M. Diaz

Lead Independent Director

--

Dr. Douglas A. (Doug) Treco, Ph.D.

Chairman of the Board, Chief Executive Officer

--

Ms. Lynne Sullivan, CPA

Independent Director

--

Mr. Erik Harris

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Axel Bolte

Director

266.70K

--

Dr. Matthew Winton, Ph.D.

Chief Operations Officer

7.39K

--

Dr. Robert (Rob) Hopfner, Ph.D.

Independent Director

--

Dr. Martin William Edwards, M.D.

Independent Director

--

Mr. Edward T. Mathers

Independent Director

--

Dr. Sarah M. Bhagat, Ph.D.

Independent Director

--

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionäre

Update-Zeit: Fri, May 16

Aktionärsstatistik

Art

Aktionärsstatistik

Aktionäre

Anteil

Longitude Capital Management Co., LLC

9.05%

Adage Capital Management, L.P.

7.99%

Pivotal Bioventure Partners Investment Advisor LLC

6.96%

Sofinnova Investments, Inc

6.63%

Affinity Asset Advisors LLC

5.99%

Other

63.38%

Aktionärsstatistik

Aktionäre

Anteil

Longitude Capital Management Co., LLC

9.05%

Adage Capital Management, L.P.

7.99%

Pivotal Bioventure Partners Investment Advisor LLC

6.96%

Sofinnova Investments, Inc

6.63%

Affinity Asset Advisors LLC

5.99%

Other

63.38%

Art

Aktionäre

Anteil

Hedge Fund

30.25%

Venture Capital

29.01%

Investment Advisor/Hedge Fund

12.31%

Investment Advisor

11.71%

Research Firm

0.92%

Corporation

0.69%

Private Equity

0.68%

Individual Investor

0.54%

Bank and Trust

0.10%

Other

13.80%

Institutionelle Beteiligung

Update-Zeit: Tue, Mar 4

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q1

216

60.54M

94.21%

-7.78M

2024Q4

214

60.27M

93.82%

-9.91M

2024Q3

191

62.40M

99.19%

-7.69M

2024Q2

189

61.61M

98.84%

-3.38M

2024Q1

182

57.68M

93.47%

-8.16M

2023Q4

168

57.62M

93.40%

-5.18M

2023Q3

173

55.08M

89.40%

+6.47M

2023Q2

167

38.83M

84.32%

-10.19M

2023Q1

159

36.61M

84.56%

-4.82M

2022Q4

151

33.67M

83.45%

-6.75M

Aktionärsaktivitäten

Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Longitude Capital Management Co., LLC

5.84M

9.09%

--

Apr 22, 2024

Adage Capital Management, L.P.

5.16M

8.03%

-513.63K

-9.05%

Dec 31, 2024

Pivotal Bioventure Partners Investment Advisor LLC

4.49M

7%

--

Dec 31, 2024

Sofinnova Investments, Inc

4.28M

6.66%

--

Dec 31, 2024

Affinity Asset Advisors LLC

3.97M

6.18%

+1.15M

+40.75%

Dec 31, 2024

Rock Springs Capital Management LP

3.86M

6.01%

+59.10K

+1.55%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

3.49M

5.43%

+313.70K

+9.87%

Dec 31, 2024

The Vanguard Group, Inc.

2.63M

4.1%

+8.91K

+0.34%

Dec 31, 2024

New Enterprise Associates (NEA)

2.44M

3.79%

--

Dec 31, 2024

Samsara BioCapital, LLC

1.56M

2.43%

--

Dec 31, 2024

Verbundene ETFs

Update-Zeit: Tue, May 6

Name

Anteil

Invesco Nasdaq Biotechnology ETF

0.01%

ProShares Ultra Nasdaq Biotechnology

0.01%

iShares Micro-Cap ETF

0.01%

iShares Russell 3000 ETF

0%

iShares Russell 2000 ETF

0%

Dimensional US Core Equity 1 ETF

0%

Fidelity Nasdaq Composite Index ETF

0%

Global X Russell 2000 ETF

0%

Global X Russell 2000 Covered Call ETF

0%

DFA Dimensional US Core Equity Market ETF

0%

Invesco Nasdaq Biotechnology ETF

Anteil0.01%

ProShares Ultra Nasdaq Biotechnology

Anteil0.01%

iShares Micro-Cap ETF

Anteil0.01%

iShares Russell 3000 ETF

Anteil0%

iShares Russell 2000 ETF

Anteil0%

Dimensional US Core Equity 1 ETF

Anteil0%

Fidelity Nasdaq Composite Index ETF

Anteil0%

Global X Russell 2000 ETF

Anteil0%

Global X Russell 2000 Covered Call ETF

Anteil0%

DFA Dimensional US Core Equity Market ETF

Anteil0%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split

Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

Inozyme Pharma Inc

3.950USD